Can liposomal amphotericin B be used as a preventive measure for cryptococcal meningitis?
- PMID: 41022650
- PMCID: PMC12648203
- DOI: 10.1080/14787210.2025.2569051
Can liposomal amphotericin B be used as a preventive measure for cryptococcal meningitis?
Keywords: Cryptococcal antigenemia; cryptococcal meningitis; cryptococcosis; liposomal amphotericin B; prevention.
Conflict of interest statement
Declaration of Interests
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
References
-
- World Health Organization. Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy, July 2017. World Health Organization; 2017. Accessed July 27, 2023. https://apps.who.int/iris/handle/10665/255884 - PubMed
-
- Rajasingham R, Govender NP, Jordan A, et al. The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. Lancet Infect Dis. 2022;22(12):1748–1755. doi: 10.1016/S1473-3099(22)00499-6 - DOI - PMC - PubMed
-
a.* Rajasingham et al. provide the most up-to-date global estimates of HIV-associated cryptococcal antigenemia, cryptococcal meningitis, and related mortality.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources